The spatiotemporal control of somatic mutagenesis in mice is considered a promising step to determine the function of a given gene product in a defined population of cells at any given time during animal life and also to generate better mouse models of human diseases. To introduce defined mutations in a temporally controlled manner in the liver, we established transgenic mice expressing a tamoxifen-inducible Cre recombinase under the control of the transthyretin promoter (TTR-Cre ind ). The recombinase activity was examined on 2 different floxed alleles by crossing TTR-Cre ind mice with either the reporter strain ROSA 26 or with homozygous mice carrying floxed catalytic ␣2 subunit of the adenosine monophosphate (AMP)-activated protein kinase gene. By placing 2 mutated hormone-binding domains of murine estrogen receptor (Mer) at both termini of the Cre, we show that the fusion protein is active only on administration of the synthetic estrogen antagonist 4-hydroxytamoxifen (4-OHT) without any background in the absence of the inducing agent. The recombination is specific of the fetal and adult liver, and we show that the efficiency of recombination reached 80% to 100% after treatment with 4-OHT. In conclusion, TTR-Cre ind transgenic mice represent a valuable tool for temporally controlling the desired gene modifications in vivo in the fetal and adult liver. This would certainly help to understand the physiologic functions of genes in the liver, to create various mouse models mimicking human diseases, and to contribute to liver cancer-specific suicide gene therapy studies.
T he liver plays a central role in the regulation of carbohydrate, lipid, and urea metabolism as well as in the production of most plasma proteins and detoxification of exogenous chemicals. The ability to create defined genetic modifications in vivo provides a powerful strategy to understand relevant functions of numerous hepatic genes in health and disease. Germline genome modification methods in which an endogenous gene is mutated throughout the life of the organism are widely used. However, these classic constitutive approaches often result in embryonic lethality when the mutated genes encode proteins that play essential functions during development. 1, 2 In addition, they could lead to complex pleiotropic phenotypes in the case of genes that exert multiple functions in distinct cell types. Furthermore, the effects of germline mutations may also be fully compensated during development, thus preventing abnormal phenotypes at later stages. To circumvent all these limitations, spatiotemporally controlled somatic mutagenesis systems are required. The main approach to achieve such conditional gene manipulations is the use of the Cre-loxP system in transgenic animals. The Cre is a 38-kDa recombinase protein from the bacteriophage P1 that recognizes the 34 -base pair (bp) loxP target sequence. The recombination occurs between 2 loxP sequences in the absence of any additional cofactors. The intramolecular recombination of 2 loxP sites oriented either head-to-head or head-to-tail results in an inversion or deletion of the intervening sequences, respectively, and an intermolecular recombination causes integration or recip-rocal translocation at the loxP site. The basic strategy for Cre-loxP-directed genetic engineering is to insert loxP sites into chromosomes by homologous recombination in ES cells and then to deliver Cre to recombine them as required. By using transgenic mice carrying the Cre recombinase under the control of a liver-specific promoter, the spatial window of gene modification can be strictly fixed to the liver. [3] [4] [5] As for the temporal control of the Cre expression in the liver, it is possible by using adenoviruses carrying the Cre transgene. [6] [7] [8] However, the immune response leads to elimination of infected cells and could have deleterious effects on the general health status of mice. 9 An alternative approach for the temporal regulation of the Cre activity is to create chimeric Cre fused to mutated ligand-binding domains of steroid hormone receptors insensitive to the endogenous ligands but still responsive to synthetic drugs. [10] [11] [12] [13] By combining the use of liver-specific promoters driving the expression of the Cre and a ligand-activated Cre, gene modifications could be finely achieved in the liver at selected time points.
In this study, we describe transgenic mice expressing a ligand-dependent recombinase Cre specifically active in the fetal and adult liver without any background recombination in the absence of the synthetic inducer. The efficiency of the inducible Cre recombinase was shown on 2 different floxed alleles, demonstrating its efficacy independently of the chromosomal locus. This mouse strain represents a valuable tool for understanding the physiologic functions of genes in the liver because gene modifications in the fetal and adult liver could be tightly controlled in vivo as desired.
Materials and Methods
All animals used in these experiments received humane care according to the criteria outlined in the European Convention for the Protection of Laboratory Animals.
Plasmids. A complementary DNA encoding a chimeric Cre fused at both N-and C-termini to the mutated hormone-binding domain of the murine estrogen receptor (amino acids 281-599, G525R) was obtained by HindIII digestion of the pAN-MerCreMer vector (kindly provided by Dr. Michael Reth), blunt ended with Klenow fragment of DNA polymerase I, and cloned into the unique StuI site of the pTTR1ExV3 (kindly provided by Dr. Terry A. Van Dyke). The pTTR1ExV3 expression vector contains transcriptional regulatory sequences from the murine transthyretin (TTR) gene consisting of 3 kb of 5Ј regulatory sequences as well as the first exon and intron and much of the second exon fused to the simian virus 40 3Ј end and poly(A) sequences. The ATG start codons of each exon have already been mutated. 14 The resulting construct TTR-MerCreMer was confirmed by sequence analysis. All techniques used for plasmid construction have been described. 15 Production and Screening of Transgenic Mice. The plasmid TTR-MerCreMer was digested with HindIII to generate a 7.4-kb transgene fragment that was separated by gel electrophoresis, purified, and injected into pronuclei of (B6D2F1 ϫ B6D2F1) fertilized eggs. Founders TTR-Cre ind were screened by Southern blot of EcoRI-digested genomic DNA extracted from tail samples, and their transgenic offspring were identified by polymerase chain reaction analysis using 2 sets of primers simultaneously: 5Ј-CCTGGAAAATGCTTCTGTC CG-3Ј and 5Ј-CAGGGTGTTATAAGCAATCCC-3Ј, which amplify a 400-bp fragment from Cre, and 5Ј-CCAC-CATGAGCCAGCAGTAATAC-3Ј and 5ЈTTGAAG-CGTCCAATTATCACCC-3Ј, amplifying 600 bp from upstream stimulatory factor 1 gene as internal control. B6D2F1 founder transgenic mice are presently being crossed into the C57Bl/6 genetic background to generate a strain more suitable for traditional gene-targeting manipulations.
To verify the transgene expression, 100 g of liver protein extracts from 4-month-old transgenic mice was subjected to Western blot using rabbit Cre-specific antisera at a dilution of 1:1,000 (Covance, Princeton, NJ). The procedure of the Western blot and revelation were performed as previously described. 16 Targeting of the ␣2 Subunit of the Adenosine Monophosphate-Activated Protein Kinase Locus. A mouse 129 strain genomic library (Stratagene, Loyola, CA) was screened with a mouse ␣2 adenosine monophosphate-activated protein kinase (AMPK) 500-bp fragment made by reverse-transcription polymerase chain reaction on liver messenger RNA using the forward 5Ј-GGAT-GCCACCTCTCATAGCA-3Ј and the reverse 5Ј-TG-ACTGCCCAGGCGCGGGG-3Ј primers. One clone encompassing a 15.7-kb fragment was used to generate the targeting construct. This fragment contains the exon encoding the C-terminus part of ␣2 AMPK catalytic domain (corresponding to amino acids 189-260 and termed exon C). The 5Ј arm of homology consists of a 3-kb XbaI-PflmnI fragment containing exon C surrounded by 2.1-kb upstream and 1.0-kb downstream intronic sequences. To introduce a loxP site, a double-stranded oligonucleotide, 5Ј-CATAACTTCGTATAATGTAT-GCTATACGAAGTTATAAGCTTCCATG-3Ј and 5Ј-CTTCGAAATAACTTCGTATAGCATACATTA-TACGAAGTTATCGTAC-3Ј (C-loxP-HindIII-SphI), was cloned 300 bp upstream of exon C into a SphI site. The insertion and orientation of the oligonucleotide were confirmed by sequencing. The 3Ј arm of homology con-sisted of a 4.2-kb PflmnI-XbaI fragment containing intronic sequences downstream of exon C. Both 5Ј and 3Ј arms of homology were cloned in a backbone KS Bluescript vector containing a PGK promoter-driven neomycine selection cassette flanked by 2 loxP sites. All information concerning the targeting construct can be obtained on request. Embryonic stem cells (MPI; a kind gift from A. K. Voss, Gottingen, Germany) were electroporated with the linearized targeting construct as previously described. 17 The G-418 -resistant clones were screened for homologous recombination by Southern blotting of HindIII-digested DNA using a flanking 5Ј probe. Seven of 230 analyzed ES cells were found to be correctly targeted, and 2 of these were transiently transfected with the pIC-Cre expression plasmid to delete the selection cassette. Deletion of the neo cassette was assessed by Southern analysis. The resulting floxed allele containing single loxP sites upstream and downstream exon C of the ␣2 AMPK gene is schematically represented in Fig. 1 . Cells that were heterozygous for this floxed allele were injected into C57BL/6 blastocysts. The blastocysts were then inserted into foster mothers according to standard methods. Chimeric male mice were crossed with C57BL/6 female mice to generate heterozygous floxed/ wild-type allele mice, and heterozygous mice were mated to generate homozygous mice.
Mating. Homozygous floxed catalytic ␣2 subunit of the AMPK mice (AMPK floxed ) were produced in our animal facilities (Paris, France). Breeding of homozygous mice AMPK floxed and TTR-Cre ind mice resulted in double-heterozygous animals that were analyzed for Cre recombination patterns of the floxed DNA in this targeted gene by Southern blot of HindIII-digested genomic DNA with internal genomic probe shown in Fig. 1 .
The ROSA26 reporter strain 18 was kindly provided by Dr. P. Soriano. Segregation of the lacZ transgene was monitored by polymerase chain reaction using specific primers: 5Ј-TGAAGCAGAAGCCTGCGATGTC-3Ј and 5Ј-CTTCATCCACCACATACAGGC-3Ј.
Ligand Administration. A total of 10 mg/mL 4-hydroxytamoxifen (4-OHT) solution (Sigma Chemical Co., St. Louis, MO) was prepared as previously de- scribed. 19 One milligram of this solution was injected intraperitoneally into mice for 5 consecutive days. For repetitive series of injection, mice were re-treated for 5 consecutive days 2, 4, and 6 weeks later. For pregnant female mice, 1 or 2 consecutive injections of 1 mg/day 4-OHT were performed at 9.5 days postcoitum (dpc) or 13.5 dpc, and embryos were collected, respectively, at 11.5 dpc or 15.5 dpc. Sunflower oil was injected as a control.
Blotting of Genomic DNA. Genomic DNA was extracted from tail and tissue biopsy specimens by proteinase K (Roche, Indianapolis, IN) digestion as detailed. 17 Ten micrograms of DNA was digested with EcoRI or HindIII for 6 hours, separated by electrophoresis in a 0.8% agarose gel, and transferred by capillarity onto nylon membrane (Hybond Nϩ, Amersham, Les Ulis, France) in the presence of 0.4 M sodium hydroxide. Hybridizations were performed overnight at 65°C with the respective 32 P-radiolabeled DNA probes: full-length Cre complementary DNA prepared from pAN-MerCreMer by a double-digestion Sal I-ClaI, and a 1.5-kb genomic probe from the AMPK ␣2 targeting construct. For quantification, blots were exposed to phosphoimager screens and analyzed using a STORM850 Phosphoimager (Molecular Dynamics, Sunnyvale, CA) and ImageQuant 5.0.
␤-Galactosidase Staining. Cryostat sections (10 m) obtained from frozen liver biopsy specimens in OCT compound (Miles Scientific, Elkhardt, IN), fresh embryos, and fetal livers were fixed for 15 minutes to 1 hour in a fixative solution (2% formaldehyde, 0.2% glutaraldehyde, 0.02% Nonidet P40, and 0.01% [w/v] deoxycholate sodium in phosphate-buffered saline [PBS]), washed twice for 10 minutes in cold PBS, and stained overnight at 30°C in X-Gal reaction buffer (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 , and 2 mM X-Gal in PBS). The stained samples were rinsed twice with PBS for 10 minutes and postfixed in the fixative solution. Embryos and fetal livers were digitally photographed; fetal livers were embedded in paraffin, and 5-m sections were obtained. Slides were counterstained with nuclear red or hemalum, dried, and cover mounted with Eukitt.
Immunohistochemical Detection. Livers were dissected from 4-OHT-treated or -nontreated (oil) doubletransgenic TTR-Cre ind/ROSA26 mice, fixed in 4% paraformaldehyde in PBS at 4°C overnight, dehydrated, and embedded in paraffin. Five-micrometer sections of liver were collected on Superfrost Plus slides (Fisher, Pittsburgh, PA), dried on a 37°C slide warmer overnight, and processed for immunohistochemistry using the EnVisionϩ kit (DAKO, Trappes, France) according to the manufacturer's methods. The primary antibodies against ␤-galactosidase (Tebu, Frankfurt, Germany) and Cre (Covance) were diluted at 1:400 and 1:500, respectively, before use. Slides were counterstained with hemalum, dried, and cover mounted with Eukitt.
For hepatic nuclear factor (HNF) 4 immunohistochemistry, 5-m sections of paraffin-embedded fetal livers from TTR-Cre ind/ROSA26 embryos already stained for ␤-galactosidase were subjected to microwave for 10 minutes in an antigen-unmasking solution (Vector, Burlingame, CA) and incubated for 15 minutes at 4°C in PBS containing 1% (w/v) bovine serum albumin and 0.25% Nonidet P40. The sections were blocked with normal goat serum (Vector; 1:20 dilution) and incubated for 1 hour at room temperature with polyclonal rabbit anti-HNF-4 antibody diluted at 1:50 (kindly provided by Moshe Yaniv, Institut Pasteur, Paris). After 3 washes in PBS, sections were incubated for 30 minutes with biotinylated anti-rabbit antibody (Vector; 1:200 dilution) and for 30 minutes with avidine coupled to peroxidase (Vector; 1:100 dilution). Revelation was performed with vasoactive intestinal polypeptide substrate according to the manufacturer's protocol (Vector).
Cell Culture. Hepatocytes were isolated from doubletransgenic TTR-Cre ind/AMPK floxed mice by the collagenase perfusion method followed by low-speed, isodensity Percoll centrifugation. 20 Cells were cultured in 199 medium (Gibco-BRL, Gaithersburg, MD) containing 10% (v/v) fetal calf serum (Gibco-BRL), 5 mM glucose, 20 nM insulin, 1 M triiodothyronine, and 1 M dexamethasone and supplemented with penicillin and streptomycin. Twenty-four hours after plating, the medium was replaced every 24 hours with fresh medium containing 500 nM to 5 M 4-OHT dissolved in ethanol. Ethanol was used as control condition. Cells were scraped 72 hours after plating, and genomic DNA was extracted and subjected to Southern blotting as previously detailed.
Results and Discussion
The Gly to Arg mutation at position 525 in the ligandbinding domain of mouse estrogen receptor (Mer) renders this domain insensitive to the natural agonist 17␤-estradiol but still responsive to the synthetic antagonist 4-OHT. 21 When this mutated domain was placed on both ends of the Cre recombinase, the activity of the chimeric protein (MerCreMer) becomes regulated by 4-OHT. 12 As described in Fig. 2A , in the absence of 4-OHT, the chimeric Cre is complexed by the heat shock protein Hsp90 and retained in the cytoplasm. In the presence of 4-OHT, the fusioned Cre is released from the Hsp90 and is translocated into the nucleus, where it can recognize the specific target loxP and recombine the floxed DNA sequence. 13, 22, 23 In cultured cells, the protein MerCreMer has been shown to be more tightly controlled by 4-OHT than the chimeric Cre with a fusion of Mer at C-terminus only (CreMer). 22 To achieve hepatic expression of MerCreMer fusion protein in transgenic mice, we used, as detailed in Fig. 2B , transcriptional regulatory sequences from the TTR gene, which encodes a serum thyroid hormone carrier produced in hepatocytes. 24 These upstream sequences of the TTR gene have been shown to target transgene expression specifically to the liver. 14, 25 Five stable transgenic lines (TTR-Cre ind ) were obtained. Expression of the MerCreMer protein was examined by Western blotting of protein extracts from transgenic adult liver, and 2 of these lines (A and B) expressed the chimeric recombinase at a same significant level (Fig. 2C) . For further studies, only line B was selected.
Because the accessibility of the loxP sites in floxed genes could influence the recombination efficiency, we tested the recombinase activity on 2 different floxed alleles by crossing the line B with the reporter strain ROSA26 18 and with homozygous mice with floxed catalytic ␣2 subunit of the AMPK gene (AMPK floxed ). In the ROSA26 line, the cassette loxP-neomycin-loxP-lacZ is targeted within the ubiquitously expressed ROSA26 locus and ␤-galactosidase is produced only after Cre-mediated excision of the loxP-flanked neomycin.
Adult (8 weeks old) double-heterozygous TTR-Cre ind/ROSA26 and TTR-Cre ind/AMPK floxed mice were injected intraperitoneally for 5 days with 1 mg 4-OHT or with control sunflower oil and were killed 1 week after the last injection. X-Gal staining was performed on TTR-Cre ind/ROSA26 liver cryosections. As shown in Fig. 3 , blue staining was observed in the livers of mice injected with 4-OHT, whereas no X-Gal staining was observed in livers of mice treated with oil. These results clearly show that the activity of the recombinase MerCreMer was fully regulated and was dependent on 4-OHT binding to the Mer in the liver of the double-heterozygous mice. The efficiency of MerCreMer-mediated recombination was about 50% in these treated mice. To further assess the Cre recombinase activity, Southern blots were performed on genomic DNA from double-heterozygous TTR-Cre ind/ AMPK floxed mice treated either with 4-OHT or control oil. The MerCreMer activity was reflected by the conversion of the 2-kb floxed allele fragment into a 3.8-kb excised allele fragment. Figure 3 shows that the Cre recombination occurred specifically in the liver of 4-OHT-treated animals only. No recombination was observed in pancreas, intestine, spleen, lung, kidney, brain, adipocytes, muscle, and heart in 4-OHT-or oil-treated mice ( Fig. 1 and data not shown) . The liver-specific recombination after 5 injections of 1 mg 4-OHT to TTRCre ind/AMPK floxed mice was quantified. Again, the efficiency of recombination reached 50% as for the ROSA reporter locus. These observed efficiencies of MerCreMer recombination may potentially be attributed to low expression level of the recombinase or to insufficient local concentrations of 4-OHT. However, the expression levels of the chimeric MerCreMer seemed to be sufficient to recombine efficiently almost all the floxed alleles in primary culture of hepatocytes isolated from adult doubletransgenic mice TTR-Cre ind/AMPK floxed incubated in the culture medium containing 4-OHT. Indeed, the excision of the floxed alleles specifically occurred in the presence of 4-OHT in a dose-dependent manner, and the recombination reached about 80% at 0.8 M (Fig. 4) . The remaining nonexcised alleles were most likely due to the presence of cells other than hepatocytes in the culture. Increasing the percentage of the excision in vivo seemed to be possible on elevation of the local concentration of the inducing drug by repetitive injections. At 20 weeks of age, the double-transgenic TTR-Cre ind/ROSA26 and TTR-Cre ind/AMPK floxed mice were injected with 4-OHT (1 mg during 5 days) and then re-treated for 5 consecutive days 2, 4, and 6 weeks later, as it has already been used. 26 After these repetitive series of injections, 80% of AMPK floxed alleles were converted into excised alleles in the liver (Fig. 5A ) and a uniform profile of lacZ staining throughout the liver was shown by immunohistochemical ␤-galactosidase detection (Fig. 5B) . Because the regulatory regions of the TTR gene used here achieved a transgene expression specifically in hepatocytes that represent 70% to 80% of liver cells, 14, 24, 25 the recombination frequency in adult hepatocytes would probably be greater than 80%.
The endogenous TTR transcripts were previously detected in early postimplantation embryos (6-7.5 days of gestation). 27 Moreover, the TTR promoter used in this study has already been reported to be active at 12.5 dpc in the developing liver. 28 Therefore, we decided to examine the developmental expression and activity of the chimeric Cre in our transgenic strain. To this end, pregnant female TTR-Cre ind/ROSA26 mice were injected intraperitoneally with 4-OHT at different stages of liver development. To prevent the antiestrogenic effects of 4-OHT and maintain pregnancy without significant embryonic lethality, we have tested and chosen to inject pregnant mice with 1 mg/day 4-OHT for 1 or 2 consecutive days (from 9.5 dpc or 13.5 dpc) before embryo collection at 11.5 or 15.5 dpc, respectively. Identical doses of 4-OHT have successfully been used during uterine development by other groups. 29 The MerCreMer-mediated recombination was analyzed by staining embryos for ␤-galactosidase activity. First, we found that no recombination occurred when pregnant female mice were injected with control oil; indeed, in the absence of the inducer, no blue staining was observed in the liver of double-heterozygous TTR-Cre ind/ROSA26 embryos ( Fig. 6A and B) . In the doubleheterozygous embryos subjected to 4-OHT treatment (1 or 2 injections), the Cre-mediated recombination occurred specifically in the fetal liver. The recombinationmediated activation of the reporter lacZ seemed more efficient with double injection of 1 mg 4-OHT (Fig. 6A  and B) . To assess the chimeric Cre recombinase activity at the cellular level in the fetal liver, we performed sections on livers of 4-OHT-treated double-heterozygous TTRCre ind/ROSA26 embryos already stained for ␤-galactosidase. Figures 6C.1 and 6C.2 show that ␤-galactosidase staining was limited to prehepatocytes, which are recognizable as large cells with a large irregular nucleus. No ␤-galactosidase staining was observed in the differentiating erythropoietic cells identified on the basis of their smaller size and highly condensed and deeply staining nuclei. HNF-4, which is a nuclear transcription factor required for hepatocyte differentiation, 30 was previously reported to be expressed in prehepatocytes and not in differentiating hematopoietic cells by using in situ hybridization of HNF-4 messenger RNA. 31 Therefore, we decided to detect the HNF-4 expression in these fetal liver sections. Colocalization of ␤-galactosidase staining and HNF-4 detection was observed, as indicated by red arrows in Figure 6C .3, showing the specific activity of the chimeric Cre in the prehepatocytes in the fetal liver of 4-OHT-treated embryos.
Taken together, our results show a strictly ligand-dependent recombinase Cre that is active in the fetal and adult liver. Three groups have already described the generation and characterization of transgenic mice carrying the Cre recombinase under the control of constitutive liver-specific promoters. [3] [4] [5] These investigators used constructs in which either the mouse albumin regulatory elements and the ␣-fetoprotein enhancers 3 or the promoter and upstream enhancer of the rat albumin gene 4, 5 were used to drive the Cre recombinase expression. These lines, AlfpCre, 3 AlbCre, 4 and Albumin-cre, 5 allow precise targeting of gene modifications in the liver. Nevertheless, the timing of recombination remains strictly dependent on the promoter activity in these transgenic mice. In AlfpCre mice, Cre was shown to be constitutively active shortly after the appearance of the liver bud. 3 Using the AlfpCre mice, the mutagenesis of hepatic genes that serve essential functions during development can result in embryonic lethality, thus precluding analysis of their putative functions at subsequent stages. In addition, the effects of a mutation could be compensated during development, thus masking abnormal phenotype in the adult animal. These limitations could be overcome using an inducible system as our strain TTR-Cre ind, which offers the possibility of making somatic mutagenesis in the liver of postnatal mice without any developmental inconvenience. Conversely, in AlbCre mice, 4 the efficiency of recombination is only about 40% immediately after birth and is complete by 6 weeks of age. 4 Similarly, Albumin-cre 5 is active only 10 days after birth. This precludes the use of AlbCre and Albumin-cre mice for the introduction of mutations at early stages to analyze physiologic functions of hepatic genes during embryogenesis and the perinatal period, whereas TTR-Cre ind can intervene at these stages. Therefore, the TTR-Cre ind strain represents a powerful system that allows generation of somatic mutations in a defined hepatic gene at a given time in the mouse life. An inducible hepatic Cre has already been reported. 32, 33 These investigators used the human ␣ 1 -antitrypsin promoter to drive the expression of a chimeric Cre fused to its carboxy terminus to a mutated (G521R) ligand-binding domain of the human estrogen receptor. This engineered Fig. 6 . Inducible MerCreMer-mediated recombination in the fetal liver. Representative embryos at (A) 11.5 dpc and (B) lobes of fetal livers at 15.5 dpc in which recombination occurred in the presence of 4-OHT in the zygotes carrying both MerCreMer and ROSA26 transgenes and resulting in ␤-galactosidase activity. Pregnant female mice were subjected to 1 or 2 consecutive intraperitoneal injections of 1 mg/day 4-OHT at 9.5 dpc or 13.5 dpc. Embryos were collected at 11.5 dpc or 15.5 dpc, respectively. Sunflower oil was injected as a control. lu, lung; h, heart; li, liver; in, intestine. recombinase is expressed only in the postnatal liver, thus limiting the window of time for gene modifications. Our strain offers the opportunity for recombinase to act at any desired time following the bud stage of the liver. Furthermore, the strain produced by Imai et al. 32, 33 shows a low recombination efficiency, making it useful only to produce genetic chimeras but not suitable for hepatic gene inactivation. For this latter strategy, our strain TTR-Cre ind seems more appropriate because we showed a very high recombination efficiency in the liver. Moreover, TTR-Cre ind transgenic line could be used in gain-offunction experiments in which expression of a transgene could be induced in the liver at any desired time. Such a transgene would be separated to a given promoter, active in the liver, by a floxed stop sequence to prevent translation of the transgene until Cre-mediated excision of the stop cassette. In this manner, a transgene could be activated in the liver, bypassing the deleterious effects of constitutive expression of transgenes like oncogenes, which frequently result in prenatal or postnatal death. By lowering the dose and changing the time of 4-OHT injection, it would also be possible to modulate the efficiency of recombination in the adult and fetal liver. This could be a considerable advantage in some approaches, allowing the production of genetic mosaics in which gain or loss of function is restricted to a certain number of hepatocytes in a wild-type background. The presence of a mixed population of wild-type and recombined cells may offer the advantage of allowing wild-type/mutant comparisons in the same animal. An internal comparison can then be varied by use of differential ligand administration regimes to generate populations with different ratios of wild-type and recombined cells.
In conclusion, our hepatic inducible chimeric Cre mice will allow temporally controlled gene modifications in the liver. Such applications will certainly permit a better understanding of hepatic gene functions and create various mouse models mimicking human diseases.
